Precision Oncology and Cancer Biomarkers : Issues at Stake and Matters of Concern.
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing AG,
2022.
|
| Edition: | 1st ed. |
| Series: | Human Perspectives in Health Sciences and Technology Series
|
| Subjects: | |
| Online Access: | Click to View |
Table of Contents:
- Intro
- Preface: What Is Responsible Cancer Research?
- Anticipatory and Reflexive - The Importance of Sociotechnical Imaginaries
- Inclusive - The Relationship to the Public
- Responsive - Are There Any Roads from Criticism to Action?
- References
- Acknowledgements
- Contents
- Introduction
- References
- Introduction to the Imaginary of Precision Oncology
- Precision Medicine - Tradition, Evidence, Reason and Ambition
- Precision Oncology - Expectations and Realisations
- Precision Medicine and the Complexity of Biological Systems
- The Imaginary of Precision Medicine and Unintended Consequences
- References
- Precision Oncology in the News
- Introduction
- Framing Within the News Media
- Identifying Frames Within the Discourse on Priority-Setting and Cancer
- Precision Medicine as a Medical Revolution
- Discussion
- Why Have the Premises Remained Unchallenged?
- Cancer and Cancer Research: An Issue of More Than Tragic Choices?
- Alternative Imaginaries
- Lack of Nuance in the Field of Cancer and Cancer Research: Why?
- Conclusion
- References
- Cancer Currencies: Making and Marketing Resources in a First-in-Human Drug Trial in Denmark
- Introduction
- Cancer Currencies and Trial Qualities
- Unit One : A Research Business at the Heart of a Public Hospital
- Fast-Tracking Trialling at the Unit
- Competitive Enrolment
- Producing Good Care and Good Science Fast
- The Genomic Project: An Investment in Potentiality
- Research Bodies: High Patient Compliance
- Discussion
- References
- "Reconstruction of Trouble"
- Introduction: The Special Status of Breast Cancer in Society
- A Case Study of How Breast Reconstruction Was Prioritised, and the Unintended Consequences This Had for Breast Cancer Patients and Other Patient Groups
- The Actors and Their Roles in the Prioritisation Game.
- Debate, Decision-Making and Their Consequences
- References
- Lost in Translation
- A Short Introduction to Health, Illness and Disease in the Context of Ovarian Cancer
- Perspectives and Concepts of Disease and Illness in Health
- A Brief Introduction to Ovarian Cancer - "The Silent Killer"
- Biomarkers in Epithelial Ovarian Cancer
- The Journey and Trajectory of Ovarian Cancer
- Anne - The Suspicion of Something Being Wrong
- Intermission - Moving from Illness to Disease: Classifying Ovarian Cancer
- Anne - The Preliminary Diagnosis
- Anne - Her Experienced Symptoms Confirmed into a Diagnosis
- Jenny - The Gynaecological Oncologist Meeting Her Patient Anne
- Anne - Accepting the Decision of Surgery
- Jenny - Posing a Final Diagnosis
- Anne - The Start of Chemotherapy
- Intermission - The Dichotomy Between Illness and Disease at the Diagnosis Stage
- Anne - The Meaning of Relapse
- Jenny - Telling the Truth or Giving False Hope?
- Anne - Towards the End of Her Journey
- Intermission - The Dichotomy Between Illness and Disease at the Stage of Relapse
- Anne - Accepting the Inevitable
- The Future of Ovarian Cancer: Anne's Story in 2040
- Intermission - The Dichotomy Between Illness and Disease in an Era of Precision Medicine
- The Challenges of Communicating Illness, Disease and Health Between Patients and Clinicians
- Making Sense of and Finding Meaning Around Health, Illness and Disease
- The Meaning and Sense of Biomarkers - From a Patient Perspective
- Conclusion
- References
- HER2 Revisited: Reflections on the Future of Cancer Biomarker Research
- Introduction
- The HER2 Story
- Discovery and Basic Studies
- Biomarker Development
- Early Clinical Trials
- Revisiting the Story of HER2
- How the HER2 Story Began: Oncogene Research Gathering Steam as a 'Bandwagon'.
- Understanding the Social, Ethical and Economic Implications of the HER2/Oncogene Bandwagon
- Basic Science
- Diagnostic
- Treatment
- Where Are We Now? The Imaginary of Precision Oncology
- Conclusion
- References
- The Dynamics of the Labelling Game: An Essay On FLT3 Mutated Acute Myeloid Leukaemia
- References
- Crossing the Styx: If Precision Medicine Were to Become Exact Science
- Introduction
- Types of Models
- Understanding the Purpose of Formal Models
- Unification
- Prediction
- System Wide Models: Descriptive Models and Repositories of Information
- Explanation
- A Possible Tension Between the Requirements of Formal Models and the Need for Conceptual Flexibility and Ambiguity in Discovery
- The Modelling Process: The Challenges of Radical Openness and Contextuality
- A Drive Towards Computational Models
- Crossing the Styx
- References
- Publication Bias in Precision Oncology and Cancer Biomarker Research
- Challenges and Possible Implications
- Introduction
- Evidence of Publication Bias in Medical Research
- Publication Bias in Precision Oncology and Cancer Biomarker Research
- The Impact of Publication Bias on the Validity of the Scientific Literature and Contribution to the Reproducibility Crisis
- Discussion: Publication Bias in Precision Oncology and Cancer Biomarker Research
- Implications and Reflections on the Deeper Roots of the Problem
- Implications for Patients, Decision-Making in Clinical Practice and Socio-economic Aspects
- Implications for Researchers and the Scientific Community
- Reflecting on the Roots of the Problem of Publication Bias
- Conclusion
- References
- Assessing the Cost-Effectiveness of Molecular Targeted Therapies and Immune Checkpoint Inhibitors
- Introduction
- Economic Evaluation of Targeted Therapies and Checkpoint Inhibitors.
- Arrangements Specific to Decision Making Involving Oncology Medicines
- Conclusions
- References
- Real-World Data in Health Technology Assessment: Do We Know It Well Enough?
- Introduction: The Growing Importance of Data in Health Care
- Real-World Data and Big Data: Some Definitions
- Health Technology Assessment in the Era of Information Technology
- Opportunities Related to Using RWD in HTA
- Challenges of Using RWD in HTA
- What Is Next: Do We Want RDW in HTA Be the Cynosure of All Eyes?
- References
- Just Caring: Precision Health vs. Ethical Ambiguity: Can we Afford the Ethical and Economic Costs?
- Just Caring: Cancer, Targeted Therapies, and Cost Control
- Cancer: Finding the First Cell/Preventing Future Cells
- Trading off Identified Lives and Statistical Lives: Ethical Issues
- Can We Just Abandon Metastatic Cancer Patients to Save Money?
- The Transition Challenge: Efficiency versus Compassion
- Whole Genome Sequencing: Another Precision Health Ethical Challenge
- Rational Democratic Deliberation: Not Precision Ethics But "Roughly Just"
- References
- Rationing of Personalised Cancer Drugs: Rethinking the Co-production of Evidence and Priority Setting Practices
- Introduction
- Personalised Cancer Care Increases the Health Gap
- Why Plan A Might Not Work and Why the Problem Is Connected to Biomarkers
- The Co-production Perspective as an Analytic Tool
- Sustainable Future Imaginaries for Cancer Drug Priority Setting
- References
- Filled with Desire, Perceive Molecules
- Prologue: The Desire to Help
- Acute Myeloid Leukaemia
- Filled with Desire, Find the Molecule
- AML Is a Name
- Empty of Desire, Perceive Mystery
- References
- Conclusions: The Biomarkers That Could Be Born
- The Biomarkers That Cannot Be Born: The Unsustainable Political Economy of Cancer Research.
- Precision Oncology: Cartesian Dream or Nightmare?
- From Precision to Personalized Oncology: Biomarkers for Dignity?
- References
- Index.